{"url_path":"/sec/coll/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1267565/0001104659-26-079323-index.html","accession_number":"0001104659-26-079323","cik":"0001267565","ticker":"COLL","issuer_name":"COLLEGIUM PHARMACEUTICAL, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1267565/0001104659-26-079323-index.html","primary_entity_key":"0001267565","primary_entity_name":"COLLEGIUM PHARMACEUTICAL, INC"},"word_count":351,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n**(a)****Financial Statements of the Business Acquired.**\n\n \n\nThe\naudited financial statements of Corium as of and for the years ended December 31, 2025 and 2024, including the related notes\nthereto, are filed herewith as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nThe unaudited financial statements of Corium as\nof March 31, 2026 and for the three months ended March 31, 2026 and 2025, including the related notes thereto, are filed herewith as Exhibit 99.2\nand incorporated herein by reference.\n\n \n\n**(b)****Pro Forma Financial Information.**\n\n \n\nThe unaudited pro forma condensed combined balance\nsheet of the Company as of March 31, 2026 and the unaudited pro forma condensed combined statements of operations of the Company\nfor the three months ended March 31, 2026 and the year ended December 31, 2025, including the related notes thereto, giving\neffect to the Acquisition are filed herewith as Exhibit 99.3 and incorporated herein by reference.\n\n \n\n**(c)****Exhibits**\n\n \n\nExhibit No.\n \nDescription\n\n[23.1](tm2618928d1_ex23-1.htm)\n \n[Consent of Grant Thornton LLP, Corium Therapeutics Holdings, LLC’s independent auditor.](tm2618928d1_ex23-1.htm)\n\n \n \n \n\n[23.2](tm2618928d1_ex23-2.htm)\n \n[Consent of Ernst & Young LLP, Corium Therapeutics Holdings, LLC’s independent auditor.](tm2618928d1_ex23-2.htm)\n\n \n \n \n\n[99.1](tm2618928d1_ex99-1.htm)\n \n[Audited financial statements of Corium Therapeutics Holdings, LLC as of and for the years ended December 31, 2025 and 2024, including the related notes thereto.](tm2618928d1_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2618928d1_ex99-2.htm)\n \n[Unaudited condensed financial statements of Corium Therapeutics Holdings, LLC as of March 31, 2026 and for the three months ended March 31, 2026 and 2025, including the related notes thereto.](tm2618928d1_ex99-2.htm)\n\n \n \n \n\n[99.3](tm2618928d1_ex99-3.htm)\n \n[Unaudited pro forma condensed combined balance sheet of the Company as of March 31, 2026, and unaudited pro forma condensed combined statements of operations of the Company for the three months ended March 31, 2026 and the year ended December 31, 2025, including the related notes thereto.](tm2618928d1_ex99-3.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: June 30, 2026\nCollegium Pharmaceutical, Inc.\n\n \n \n \n \n\n \nBy:\n/s/ Colleen Tupper\n\n \n \nName:\nColleen Tupper\n\n \n \nTitle:\nExecutive Vice President and Chief Financial Officer"}